Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended‐Release Case Study

The objective of this research was to evaluate the impact of changes in the formulation of metoprolol extended‐release (ER) tablets on dissolution, pharmacokinetic, and exercise‐induced heart rate (EIHR) using a combined physiologically based absorption pharmacokinetic, and population pharmacokinetic/pharmacodynamic modeling and simulation approach. Using a previously developed physiologically based absorption pharmacokinetic model in DDDPlus and GastroPlus, we simulated the changes in drug release and exposure as the result of quantitative changes in the release‐controlling excipient, hydroxylpropylmethylcellulose, for 50 and 200 mg. The similarity of dissolution profiles was assessed using the f2 test, and bioequivalence was tested on the simulated pharmacokinetic profiles. We used the simulated concentration‐time profiles following formulation changes as pharmacokinetic input into a population pharmacokinetic/pharmacodynamic model newly developed in NONMEM to determine if changes in pharmacokinetics lead to clinically significant changes in pharmacodynamics. Pharmacodynamic assessment was based on the percentage reduction in the EIHR from baseline. Therapeutic effect was considered similar when the model‐predicted EIHR was within 50% to 85% of the average maximum EIHR of healthy 30‐year‐old subjects. A 40% or more increase in the release rate constant resulted in dissimilarity in dissolution profiles and bioINequivalence in pharmacokinetics for both 50 and 200 mg. Formulation‐related differences in drug release of metoprolol ER tablets can lead to differences in pharmacokinetics. However, the evaluated pharmacokinetic differences do not lead to clinically meaningful differences in EIHR, suggesting that EIHR may not be sensitive enough to detect changes in pharmacokinetics of metoprolol ER products.

[1]  Andrew C. Hooker,et al.  Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.

[2]  R. Bergstrand,et al.  Pharmacokinetic and Pharmacodynamic Evaluation of Metoprolol Controlled Release (CR/ZOK) 50 mg in Young Subjects , 1990, Journal of clinical pharmacology.

[3]  P. R. Nixon,et al.  Drug release from hydrophilic matrices. 2. A mathematical model based on the polymer disentanglement concentration and the diffusion layer. , 1995, Journal of pharmaceutical sciences.

[4]  J. Jonkman,et al.  A Pharmacokinetic and Pharmacodynamic Comparison of Metoprolol CR/ZOK with a Conventional Slow Release Preparation , 1990, Journal of clinical pharmacology.

[5]  R. Johansson,et al.  Pharmacokinetic studies on the selectiveβ1-receptor antagonist metoprolol in man , 1974, Journal of Pharmacokinetics and Biopharmaceutics.

[6]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[7]  Lawrence X. Yu,et al.  Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration , 2009, The Annals of pharmacotherapy.

[8]  Joel S. Owen,et al.  Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models , 2014 .

[9]  C. Stefanadis,et al.  The Interplay of Exercise Heart Rate and Blood Pressure as a Predictor of Coronary Artery Disease and Arterial Hypertension , 2013, Journal of clinical hypertension.

[10]  R. Brook,et al.  Influence of Metoprolol Dosage Release Formulation on the Pharmacokinetic Drug Interaction With Paroxetine , 2011, Journal of clinical pharmacology.

[11]  SRB Allerheiligen,et al.  Impact of Modeling and Simulation: Myth or Fact? , 2014, Clinical pharmacology and therapeutics.

[12]  P. Lundborg,et al.  Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: A comparison with conventional tablets , 2004, European Journal of Clinical Pharmacology.

[13]  I. Pigeot,et al.  Hospitalization rates of generic metoprolol compared with the original beta‐blocker in an epidemiological database study , 2007, Pharmacoepidemiology and drug safety.

[14]  P. Binkley,et al.  Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure. , 2006, Journal of cardiac failure.

[15]  E. Niclas Jonsson,et al.  PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM , 2005, Comput. Methods Programs Biomed..

[16]  K. Shakesheff,et al.  The effect of processing variables on morphological and mechanical properties of supercritical CO2 foamed scaffolds for tissue engineering. , 2012, Acta biomaterialia.

[17]  J. Dressman,et al.  Comparison of Drug Release From Metoprolol Modified Release Dosage Forms in Single Buffer versus a pH-Gradient Dissolution Test , 2006 .

[18]  C. Liau,et al.  Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulations of motoprolol in healthy chinese subjects , 1989, Cardiovascular Drugs and Therapy.

[19]  Using METHOCEL Cellulose Ethers for Controlled Release of Drugs in Hydrophilic Matrix Systems , 2019 .

[20]  Liang Zhao,et al.  Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended‐Release Products , 2019, Journal of clinical pharmacology.

[21]  Stephan Schmidt,et al.  An Integrated Bioinformatics and Quantitative Modeling Approach to Investigate Potential Claims of Oral Generic Drug Product Bioinequivalence: Introduction , 2019, Journal of clinical pharmacology.

[22]  N. Peppas,et al.  Mechanisms of solute release from porous hydrophilic polymers , 1983 .

[23]  Lawrence X. Yu,et al.  Innovative approaches for demonstration of bioequivalence: the US FDA perspective. , 2013, Therapeutic delivery.

[24]  M. S. Täng,et al.  Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure. , 2001, Journal of cardiac failure.

[25]  R J Keizer,et al.  Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose , 2013, CPT: pharmacometrics & systems pharmacology.

[26]  P. Lundborg,et al.  Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: A comparison with atenolol , 2004, European Journal of Clinical Pharmacology.

[27]  Ikuharu Morioka,et al.  Blood Pressure Response to Heart Rate During Exercise Test and Risk of Future Hypertension , 2002, Hypertension.

[28]  C. Meisel,et al.  Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol Pharmacokinetics and Pharmacodynamics , 2004, Clinical pharmacology and therapeutics.

[29]  M. H. Rubinstein,et al.  Studies on the interaction between water and (hydroxypropyl)methylcellulose. , 1997, Journal of pharmaceutical sciences.

[30]  Raj M. Khandwalla,et al.  Differential Effects of Carvedilol and Metoprolol Succinate on Plasma Norepinephrine Release and Peak Exercise Heart Rate in Subjects With Chronic Heart Failure , 2008, Journal of cardiovascular pharmacology and therapeutics.

[31]  P H van der Graaf,et al.  Introduction to Population Pharmacokinetic/Pharmacodynamic Analysis With Nonlinear Mixed Effects Models , 2014, CPT: pharmacometrics & systems pharmacology.

[32]  A. Setiawati,et al.  Pharmacokinetic and Pharmacodynamic Properties of Controlled Release (CR/ZOK) Metoprolol in Healthy Oriental Subjects: A Comparison with Conventional Formulations of Metoprolol and Atenolol , 1990, Journal of clinical pharmacology.

[33]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[34]  M. Metra,et al.  Differential Effects of β-Blockers in Patients With Heart Failure , 2000 .

[35]  R. Bergstrand,et al.  Pharmacokinetic and Pharmacodynamic Comparison of Metoprolol CR/ZOK Once Daily with Conventional Tablets Once Daily and in Divided Doses , 1990, Journal of clinical pharmacology.

[36]  M. Metra,et al.  Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. , 2000, Circulation.

[37]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[38]  Ping Gao,et al.  Diffusion in HPMC Gels. II. Prediction of Drug Release Rates from Hydrophilic Matrix Extended-Release Dosage Forms , 1995, Pharmaceutical Research.

[39]  J. Siepmann,et al.  HPMC-Matrices for Controlled Drug Delivery: A New Model Combining Diffusion, Swelling, and Dissolution Mechanisms and Predicting the Release Kinetics , 1999, Pharmaceutical Research.

[40]  Linda S. Henderson,et al.  Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction , 2008, Vascular health and risk management.

[41]  N. Miyai,et al.  Tatsuo Shiraishi and Hypertension Blood Pressure Response to Heart Rate During Exercise Test and Risk of Future , 2002 .

[42]  C. Regårdh,et al.  Plasma Concentrations and Beta‐Blocking Effects in Normal Volunteers After Intravenous Doses of Metoprolol and Propranolol , 1980, Journal of cardiovascular pharmacology.

[43]  Thomas O'Hara,et al.  A REVIEW OF METHODS USED TO COMPARE DISSOLUTION PROFILE DATA , 1998 .